Zobrazeno 1 - 10
of 348
pro vyhledávání: '"E. Autret-Leca"'
Publikováno v:
In Archives de pédiatrie 2002 9(4):422-428
Autor:
E. Autret-Leca, A.-P. Jonville-Béra
Publikováno v:
Archives de Pédiatrie. 19:1252-1257
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3e9504c384d71bd04c456129d6993820
https://doi.org/10.1016/j.arcped.2012.08.014
https://doi.org/10.1016/j.arcped.2012.08.014
Autor:
Jean-Louis Montastruc, E Autret-Leca, B Baldin B, F Bavoux, A Bénard-Laribière, M Biour, MN Beyens, F Colin, A Cocquerel, S Crepin, G Décréau-Gaillon, S Dos Santos, P Eftekhari, S Favrelière, S Gautier, V Gras-Champel, L Javot, MJ Jean-Pastor, C Le Beller, B Lebrun-Vignes, A Millaret, A Perrazi, V Pinzani, C Riché, E Schir, C Sgro, M Tebacher-Alt, T Trenque, MB Valnet-Rabier, G Veyrac
Publikováno v:
Bulletin de l'Académie Nationale de Médecine. 195:1309-1317
RESUME Cette etude a evalue les notifications spontanees d’effets indesirables medicamenteux (EIM) collectees sur le territoire francais entre le 21 octobre 2009 et le 15 juin 2010 pour les vaccins antiviraux A (H1N1) v. Cette campagne s’est cara
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::10857f86a220d140681da1e8070d3676
https://doi.org/10.1016/s0001-4079(19)31991-0
https://doi.org/10.1016/s0001-4079(19)31991-0
Publikováno v:
Archives de Pédiatrie. 17:1480-1487
In the last few years, several studies related to the benefit/risk balance of postnatal corticosteroids administered to premature neonates for prevention or treatment of bronchopulmonary dysplasia (BPD) have been published. These data encourage cauti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6bac6ba6d77d9fedb9a4c3fc813bb70d
https://doi.org/10.1016/j.arcped.2010.07.013
https://doi.org/10.1016/j.arcped.2010.07.013
Autor:
E. Autret-Leca
Publikováno v:
Archives de Pédiatrie. 17:1237-1242
When a new drug is labelled, before deciding its integration in the therapeutic strategy, the doctor has to know the degree of innovation of the drug, i.e. its actual benefit and the improvement of actual benefit, also called added value over other a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4dff0912bfdfe96bee294f8093244640
https://doi.org/10.1016/j.arcped.2010.05.001
https://doi.org/10.1016/j.arcped.2010.05.001
Autor:
P.. Carré, Patrice Diot, B.. Narciso, Laurent Guilleminault, K. De Luca, F.. Beau Salinas, E.. Autret-Leca
Publikováno v:
Revue des Maladies Respiratoires. 25:880-884
Introduction Le temozolomide est un agent alkylant indique en association a la radiotherapie dans le traitement des glioblastomes. Observation Nous rapportons l’observation d’une femme de 56 ans ayant presente une pneumonie alveolo-interstitielle
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::22fbeac2e725015f5011a573991f899a
https://doi.org/10.1016/s0761-8425(08)74357-2
https://doi.org/10.1016/s0761-8425(08)74357-2
Publikováno v:
EMC - Otorrinolaringología. 36:1-12
La otitis media aguda (OMA) es una de las principales razones de prescripcion de antibioticos en los ninos. Se trata de una infeccion bacteriana. En la mayoria de las ocasiones, se inicia por una rinofaringitis viral que altera el funcionamiento de l
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7830c4515ab3f754737efe9a910217e9
https://doi.org/10.1016/s1632-3475(07)70322-3
https://doi.org/10.1016/s1632-3475(07)70322-3
Publikováno v:
EMC - Otorinolaringoiatria. 6:1-11
L’otite media acuta (OMA) e una delle cause principali della prescrizione di antibiotici nei bambini. Si tratta di un’infezione batterica. Di solito inizia con una rinofaringite virale che altera il funzionamento delle tube uditive. La diagnosi s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c6b92538bd965e9e48352ffd4c522b3b
https://doi.org/10.1016/s1639-870x(07)70193-9
https://doi.org/10.1016/s1639-870x(07)70193-9
Autor:
E. Autret-Leca
Publikováno v:
Archives de Pédiatrie. 13:1144-1148
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ef6be2a4975f82c6adf9fdf794eb89f3
https://doi.org/10.1016/j.arcped.2006.05.008
https://doi.org/10.1016/j.arcped.2006.05.008
Autor:
Evelyne Jacqz-Aigrain, Véronique Lamarque, E. Autret-Leca, L. Becquemont, M.-J. Boutroy, P. Carlier, A. Castot, C. Cornu, C. Damase-Michel, J.-P. Demarez, E. Dohin, M. Gersberg, C. Kreft-Jais, H. Le Louet, F. Meillier, J.-L. Parier, G. Pons, D. Subtil, T. Vial
Publikováno v:
Therapies. 61:297-304
Data required to asses the risk of a new drug regarding the normal course of pregnancy as well as embryo, fetal and neonate development, are often missing when a new product is launched. In such a situation, a risk management plan is to be developed
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c61ab067ec4d86409625c8a8de179ace
https://doi.org/10.2515/therapie:2006057
https://doi.org/10.2515/therapie:2006057